

CORRIGENDUM

Corrigendum: Vulnerable period in heart failure: a window of opportunity for the optimization of treatment – a statement by Mexican experts

Abstract

The authors wish to make the following corrections to their article: Magaña Serrano JA, Cigarroa López JA, Chávez Mendoza A, Ivey-Miranda JB, Mendoza Zavala GH, Olmos Domínguez L, Chávez Leal SA, Pombo Bartelt JE, Herrera-Garza EH, Mercado Leal G, Parra Michel R,

Aguilera Mora LF, Nuriulu Escobar PL. Corrigendum: Vulnerable period in heart failure: a window of opportunity for the optimization of treatment – a statement by Mexican experts. *Drugs Context*. 2024;13:2023-8-1. <https://doi.org/10.7573/dic.2023-8-1>

Corrigendum

The authors regret that there are errors in their original paper.

The following shows where original text has been removed (strikethrough) and new wording introduced (underlined).

Page 7, Table 3

Table 3. Comprehensive evaluation of volume status at discharge.

Variable		Congestion			
		Euvoaemia	Mild	Moderate	Severe
Clinical evaluation	Orthopnea	No	Mild	Moderate	Severe
	Elevated jugular venous pressure/hepatojugular reflux	No	I	II	III
	Oedema	No	+	++	+++ /++++
	6-Minute walk test (meters)	300–400	200–300	100–200	<100
Complementary tests	NT-proBNP (pg/mL)	<400	400–1500	1500–3000	>3000
	Ca 125 (U/mL)	<35	>35	>35	>35
	Chest X-ray	Normal	Pulmonary venous congestion	Pulmonary venous congestion + pleural effusion	Interstitial oedema
	Vena cava imaging	<22 mm with collapsibility >50%	>22 mm or collapsibility <50%	>22 mm or collapsibility <50%	>22 mm with collapsibility <50%
	Lung ultrasound	≥15 B-lines	15–30 B-lines	15–30 B-lines	>30 B-lines

NT-proBNP, N-terminal prohormone of brain natriuretic peptide.

Table modified from ref.⁴⁰